MatchMedi
한국어

Options mapped

Uveal melanoma: options by country

Sourced options by country plus visit-prep questions for Uveal melanoma. Each line links to its regulator, HTA, or guideline source. This page maps options; it does not recommend or rank them.

Options mappedSolid tumorLast checked June 2026

What this page does

Maps options by country

It maps sourced options by country alongside diagnosis wording, stage, test results, specialists, and trial-search terms.

What it does not do

Does not choose treatment

It does not rank treatments, recommend a choice, or decide clinical fit.

Where it comes from

Built on trusted sources

Every option links to a trusted regulator, HTA, or guideline source, and the list grows as new sources pass verification.

Information to gather before the next visit

  • Has HLA-A*02:01 genotyping been performed?
  • Is the disease unresectable or metastatic uveal melanoma?
  • What monitoring setting is needed for cytokine release syndrome risk?
  • Is HLA-A*02:01 testing required and documented locally before treatment?

Trial-search terms to discuss

Uveal melanoma clinical trial

Options by country

Treatments by country

Regulatory and access status by country, from official sources. It shows what exists and where — not a recommendation.

United States

  • Melphalan for injection / Hepatic Delivery System (HEPZATO KIT; HEPZATO melphalan)[1]FDA-approvedNo HLA genotype requirement stated in the FDA/DailyMed indication; liver-metastasis distribution criteria are central to the label.; Adult uveal melanoma with unresectable hepatic metastases in the labeled liver-dominant context; FDA notes the FOCUS study included patients with unresectable hepatic metastases and limited extrahepatic disease if the life-threatening component was in the liver and extrahepatic sites had a defined treatment plan. · DailyMed and FDA describe boxed warnings for severe peri-procedural complications and myelosuppression; DailyMed states HEPZATO KIT is available only through a restricted REMS program and should be used by trained healthcare providers. The label includes contraindications and procedural restrictions; this entry does not imply an individual patient meets them. Confidence/conflicts: High; FDA approval notice and current DailyMed label align on the core U.S. indication. No conflict found.
  • Melphalan for injection / Hepatic Delivery System (HEPZATO KIT; HEPZATO melphalan)[1]FDA-approvedNo HLA genotype requirement stated in the FDA/DailyMed indication; liver-metastasis distribution criteria are central to the label.; Adult uveal melanoma with unresectable hepatic metastases in the labeled liver-dominant context; FDA notes the FOCUS study included patients with unresectable hepatic metastases and limited extrahepatic disease if the life-threatening component was in the liver and extrahepatic sites had a defined treatment plan. · DailyMed and FDA describe boxed warnings for severe peri-procedural complications and myelosuppression; DailyMed states HEPZATO KIT is available only through a restricted REMS program and should be used by trained healthcare providers. The label includes contraindications and procedural restrictions; this entry does not imply an individual patient meets them. Confidence/conflicts: High; FDA approval notice and current DailyMed label align on the core U.S. indication. No conflict found.
  • Melphalan for injection / Hepatic Delivery System (HEPZATO KIT; HEPZATO melphalan)[1]FDA-approvedNo HLA genotype requirement stated in the FDA/DailyMed indication; liver-metastasis distribution criteria are central to the label.; Adult uveal melanoma with unresectable hepatic metastases in the labeled liver-dominant context; FDA notes the FOCUS study included patients with unresectable hepatic metastases and limited extrahepatic disease if the life-threatening component was in the liver and extrahepatic sites had a defined treatment plan. · DailyMed and FDA describe boxed warnings for severe peri-procedural complications and myelosuppression; DailyMed states HEPZATO KIT is available only through a restricted REMS program and should be used by trained healthcare providers. The label includes contraindications and procedural restrictions; this entry does not imply an individual patient meets them. Confidence/conflicts: High; FDA approval notice and current DailyMed label align on the core U.S. indication. No conflict found.
  • radiation therapy, including plaque radiation therapy and external-beam charged-particle radiation therapy as described by NCI PDQ[2]NCI PDQ: standard optionlocal treatment for intraocular/uveal melanoma, including medium and large choroidal melanoma settings. · NCI PDQ notes charged-particle radiation is offered at specialized referral centers and requires careful patient cooperation. It also distinguishes radiation options by tumor extent and clinical factors.
  • surgery, including resection and enucleation as described by NCI PDQ[2]NCI PDQ: standard optionprimary intraocular/uveal melanoma local treatment; medium/large choroidal melanoma context depends on tumor size and extent. · NCI PDQ is an information summary, not a patient-specific eligibility rule. The source emphasizes treatment depends on tumor factors and clinical context.
  • tebentafusp-tebn (Kimmtrak)[3]FDA-approvedHLA-A*02:01-positive; unresectable or metastatic uveal melanoma; FDA approval notice describes IMCgp100-202 in metastatic uveal melanoma and notes patients were required to be HLA-A*02:01 genotype positive. · FDA label states patient selection is based on positive HLA-A*02:01 genotyping and that an FDA-approved test for HLA-A*02:01 genotyping was not currently available in the 2022 label. The label includes a boxed warning for cytokine release syndrome and monitoring requirements.

European Union

  • tebentafusp (Kimmtrak)[4]EMA authorisedHLA-A*02:01-positive implied by Kimmtrak product context; EMA overview states uveal melanoma cannot be removed by surgery or has spread; unresectable or metastatic uveal melanoma. · EMA states Kimmtrak should be given under supervision of a doctor experienced with cancer medicines and cytokine release syndrome, and in a setting where CRS can be managed. Member-state reimbursement, including Germany/France, was not verified in this cell. Confidence/conflicts: high for EMA-authorised status; no source conflict identified. Member-state reimbursement unverified.
  • tebentafusp (Kimmtrak)[5]ApprovedHLA-A*02:01-positive; Monotherapy for adult HLA-A*02:01-positive unresectable or metastatic uveal melanoma. · HAS notes important monitoring issues including acute skin reactions, cardiac disorders, and cytokine release syndrome in the source summary. This entry does not establish individual eligibility or availability at a specific French center. Confidence/conflicts: High for France HAS reimbursement and population scope. No conflict identified.
  • tebentafusp (Kimmtrak)[6]ApprovedHLA-A*02:01-positive; Monotherapy for adult HLA-A*02:01-positive unresectable/inoperable or metastatic uveal melanoma in the German G-BA benefit-assessment context. · Source is in German; human-language review is needed before patient-facing reuse. The entry records G-BA assessment/indication context and does not capture current negotiated price or center-level access. Confidence/conflicts: Medium-high for Germany G-BA indication/assessment context; language review required and current access implementation not captured. No conflict identified. Primary source not in English. English summary pending human review — confirm exact wording with your care team.

United Kingdom

  • tebentafusp (Kimmtrak)[7]ApprovedHLA-A*02:01-positive; HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults. · NICE states there is no standard treatment specifically for this population and that tebentafusp is recommended under the commercial arrangement. The recommendation is an NHS access appraisal, not a universal UK/private-sector availability statement.
  • tebentafusp (Kimmtrak)[8]ApprovedHLA-A*02:01-positive; Adult HLA-A*02:01-positive unresectable or metastatic uveal melanoma. · The SmPC establishes the UK product-information indication, not devolved NHS reimbursement. The SmPC flags administration under experienced supervision and cytokine release syndrome preparedness. Confidence/conflicts: High for UK SmPC indication. Devolved access differs by jurisdiction and is recorded separately below.
  • tebentafusp (Kimmtrak)[9]ApprovedHLA-A*02:01-positive; NICE technology-appraisal recommendation for adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma; used primarily as first-line treatment in committee discussion. · NICE recommendations apply to NHS commissioning contexts covered by NICE implementation rules and include a confidential commercial arrangement. They should not be generalized to Scotland without SMC verification. Confidence/conflicts: High for NICE recommendation and conditions. Conflicts with Scotland SMC non-recommendation are recorded in Finding BKJ-3.
  • tebentafusp (Kimmtrak)[9]ApprovedHLA-A*02:01-positive; NICE technology-appraisal recommendation for adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma; used primarily as first-line treatment in committee discussion. · NICE recommendations apply to NHS commissioning contexts covered by NICE implementation rules and include a confidential commercial arrangement. They should not be generalized to Scotland without SMC verification. Confidence/conflicts: High for NICE recommendation and conditions. Conflicts with Scotland SMC non-recommendation are recorded in Finding BKJ-3.
  • tebentafusp (Kimmtrak)[10]ApprovedHLA-A*02:01-positive; NHSScotland routine-use appraisal for adult HLA-A*02:01-positive unresectable or metastatic uveal melanoma. · This is a non-recommendation for routine NHSScotland use, not a statement that the drug lacks UK marketing authorization. SMC public summary says an individual request may still be considered by health boards if a clinician thinks a patient may benefit. Confidence/conflicts: High for Scotland SMC non-recommendation. Conflict/divergence noted with NICE recommendation for England/Wales contexts.
  • tebentafusp (Kimmtrak)[10]ApprovedHLA-A*02:01-positive; NHSScotland routine-use appraisal for adult HLA-A*02:01-positive unresectable or metastatic uveal melanoma. · This is a non-recommendation for routine NHSScotland use, not a statement that the drug lacks UK marketing authorization. SMC public summary says an individual request may still be considered by health boards if a clinician thinks a patient may benefit. Confidence/conflicts: High for Scotland SMC non-recommendation. Conflict/divergence noted with NICE recommendation for England/Wales contexts.

Australia

  • tebentafusp (Kimmtrak)[11]TGA-registered (Australia)HLA-A*02:01-positive; Adult HLA-A*02:01-positive unresectable or metastatic uveal melanoma. · TGA approval does not alone establish PBS subsidy, treatment-center availability, or individual eligibility. Biomarker confirmation and specialist oversight are central to the indication. Confidence/conflicts: High for Australian regulatory approval and indication. No conflict identified. Availability/reimbursement outside the approving regulator not established.
  • tebentafusp (Kimmtrak)[12]ApprovedHLA-A*02:01-positive; eviQ protocol indicates adult HLA-A*02:01-positive population and ECOG 0 to 1; PBS/eviQ access and protocol context for advanced unresectable or metastatic HLA-A*02:01-positive uveal melanoma. · PBS authority and eviQ protocol context do not establish individual PBS authority approval, inpatient billing details, or local hospital capacity. eviQ flags cytokine release syndrome monitoring and appropriate setting requirements. Confidence/conflicts: High for PBS listing status and eviQ protocol context. No conflict identified. Availability/reimbursement outside the approving regulator not established.
  • tebentafusp (Kimmtrak)[12]ApprovedHLA-A*02:01-positive; eviQ protocol indicates adult HLA-A*02:01-positive population and ECOG 0 to 1; PBS/eviQ access and protocol context for advanced unresectable or metastatic HLA-A*02:01-positive uveal melanoma. · PBS authority and eviQ protocol context do not establish individual PBS authority approval, inpatient billing details, or local hospital capacity. eviQ flags cytokine release syndrome monitoring and appropriate setting requirements. Confidence/conflicts: High for PBS listing status and eviQ protocol context. No conflict identified. Availability/reimbursement outside the approving regulator not established.

Canada

  • tebentafusp (Kimmtrak)[13]Health Canada approvedHLA-A*02:01-positive; Adult HLA-A*02:01-positive unresectable or metastatic uveal melanoma. · Health Canada authorization does not by itself establish public-drug-plan reimbursement or site availability. The SBD records monitoring and safety issues through the product monograph context. Confidence/conflicts: High for Canadian authorization and adult indication scope. No conflict identified.
  • tebentafusp (Kimmtrak)[14]ApprovedHLA-A*02:01-positive; clinically stable CNS disease or no brain metastases in CADTH conditions; First-line public-payer reimbursement recommendation for adult HLA-A*02:01-positive unresectable or metastatic uveal melanoma, with CADTH conditions. · CADTH recommendations guide Canadian public drug plans but do not prove every province or territory has implemented identical criteria. Local formulary confirmation remains needed. Confidence/conflicts: High for CADTH reimbursement conditions; province-by-province implementation remains a gap. No conflict identified.
  • tebentafusp (Kimmtrak)[14]ApprovedHLA-A*02:01-positive; clinically stable CNS disease or no brain metastases in CADTH conditions; First-line public-payer reimbursement recommendation for adult HLA-A*02:01-positive unresectable or metastatic uveal melanoma, with CADTH conditions. · CADTH recommendations guide Canadian public drug plans but do not prove every province or territory has implemented identical criteria. Local formulary confirmation remains needed. Confidence/conflicts: High for CADTH reimbursement conditions; province-by-province implementation remains a gap. No conflict identified.

Sources

  1. DailyMed / U.S. National Library of Medicine — official U.S. drug label · official U.S. drug label
  2. National Cancer Institute — national cancer agency PDQ · national cancer agency PDQ
  3. U.S. Food and Drug Administration — official drug label · official drug label
  4. European Medicines Agency — regulator product page / EPAR · regulator product page / EPAR
  5. Haute Autorite de Sante (HAS) — HTA reimbursement opinion English summary · HTA reimbursement opinion English summary
  6. Gemeinsamer Bundesausschuss (G-BA) — AMNOG benefit-assessment procedure page · AMNOG benefit-assessment procedure page
  7. National Institute for Health and Care Excellence (NICE) — health technology appraisal / guideline · health technology appraisal / guideline
  8. electronic Medicines Compendium (emc) / Immunocore — UK Summary of Product Characteristics · UK Summary of Product Characteristics
  9. National Institute for Health and Care Excellence (NICE) — technology appraisal guidance · technology appraisal guidance
  10. Scottish Medicines Consortium (SMC) — medicine advice · medicine advice
  11. Therapeutic Goods Administration (TGA) — Australian Prescription Medicine Decision Summary · Australian Prescription Medicine Decision Summary
  12. Australian Pharmaceutical Benefits Scheme (PBS) Medicine Status Website — PBS medicine status / listing record · PBS medicine status / listing record
  13. Health Canada Drug and Health Products Portal — Summary Basis of Decision · Summary Basis of Decision
  14. NCBI Bookshelf / CADTH — reimbursement recommendation table · reimbursement recommendation table

This is official regulatory and access status only — not medical advice, not a recommendation, and not a statement about eligibility. Whether any option fits depends on your situation and your oncology team. Status changes over time; confirm the current position with the linked source. Last checked 2026-06-12.

Beyond approved care

In clinical trials & emerging options

Options that are not — or not yet — an approved standard where you live: studies, clinical trials, off-label use, and early evidence that your own oncologist may not raise. Each is labeled by how strong the evidence is. A listing here is information to research and discuss with your team; it does not mean a treatment is proven, safe for you, or available today.

In clinical trials

  • Melphalan/HDS percutaneous hepatic perfusion plus tebentafusp (Kimmtrak)Clinical trial · NCT07276386Clinical trialTrial only (registry)United States · HLA-A*02:01-positive patients are described in the ClinicalTrials.gov brief summary.; Sequential percutaneous hepatic perfusion with melphalan/HDS followed by tebentafusp for metastatic uveal melanoma with isolated liver metastases; the registry describes two PHP procedures followed by tebentafusp, with additional PHP procedures possible in the protocol context. · Trial eligibility, HLA status, liver-disease pattern, center participation, and enrollment status must be confirmed through the trial team; ClinicalTrials.gov status can change. Dosing details in the registry were not reproduced as patient guidance. Confidence/conflicts: High for registry status and intervention; no conflict found. Approved HEPZATO access is captured separately in BKL-1 and should not be conflated with this investigational combination. ClinicalTrials.gov — clinical-trial registry
  • Melphalan/HDS percutaneous hepatic perfusion plus tebentafusp (Kimmtrak)Clinical trial · NCT07276386Clinical trialTrial only (registry)United States · HLA-A*02:01-positive patients are described in the ClinicalTrials.gov brief summary.; Sequential percutaneous hepatic perfusion with melphalan/HDS followed by tebentafusp for metastatic uveal melanoma with isolated liver metastases; the registry describes two PHP procedures followed by tebentafusp, with additional PHP procedures possible in the protocol context. · Trial eligibility, HLA status, liver-disease pattern, center participation, and enrollment status must be confirmed through the trial team; ClinicalTrials.gov status can change. Dosing details in the registry were not reproduced as patient guidance. Confidence/conflicts: High for registry status and intervention; no conflict found. Approved HEPZATO access is captured separately in BKL-1 and should not be conflated with this investigational combination. ClinicalTrials.gov — clinical-trial registry
  • Melphalan/HDS percutaneous hepatic perfusion plus tebentafusp (Kimmtrak)Clinical trial · NCT07276386Clinical trialTrial only (registry)United States · HLA-A*02:01-positive patients are described in the ClinicalTrials.gov brief summary.; Sequential percutaneous hepatic perfusion with melphalan/HDS followed by tebentafusp for metastatic uveal melanoma with isolated liver metastases; the registry describes two PHP procedures followed by tebentafusp, with additional PHP procedures possible in the protocol context. · Trial eligibility, HLA status, liver-disease pattern, center participation, and enrollment status must be confirmed through the trial team; ClinicalTrials.gov status can change. Dosing details in the registry were not reproduced as patient guidance. Confidence/conflicts: High for registry status and intervention; no conflict found. Approved HEPZATO access is captured separately in BKL-1 and should not be conflated with this investigational combination. ClinicalTrials.gov — clinical-trial registry
  • Melphalan/HDS percutaneous hepatic perfusion plus tebentafusp (Kimmtrak)Clinical trial · NCT07276386Clinical trialTrial only (registry)United States · HLA-A*02:01-positive patients are described in the ClinicalTrials.gov brief summary.; Sequential percutaneous hepatic perfusion with melphalan/HDS followed by tebentafusp for metastatic uveal melanoma with isolated liver metastases; the registry describes two PHP procedures followed by tebentafusp, with additional PHP procedures possible in the protocol context. · Trial eligibility, HLA status, liver-disease pattern, center participation, and enrollment status must be confirmed through the trial team; ClinicalTrials.gov status can change. Dosing details in the registry were not reproduced as patient guidance. Confidence/conflicts: High for registry status and intervention; no conflict found. Approved HEPZATO access is captured separately in BKL-1 and should not be conflated with this investigational combination. ClinicalTrials.gov — clinical-trial registry
  • RP2 plus nivolumab versus nivolumab plus ipilimumabClinical trial · NCT06581406Clinical trialTrial only (NCT06581406)United States · immune-checkpoint-inhibitor-naive adult population; no molecular biomarker requirement identified in fetched registry summary; Immune-checkpoint-inhibitor-naive adult metastatic uveal melanoma. · This is trial-only evidence. It does not establish routine access to RP2 or superiority of either arm outside the trial. Confidence/conflicts: High for registry geography and trial design; investigational RP2 component. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • RP2 plus nivolumab versus nivolumab plus ipilimumabClinical trial · NCT06581406Clinical trialTrial only (NCT06581406)United States · immune-checkpoint-inhibitor-naive adult population; no molecular biomarker requirement identified in fetched registry summary; Immune-checkpoint-inhibitor-naive adult metastatic uveal melanoma. · This is trial-only evidence. It does not establish routine access to RP2 or superiority of either arm outside the trial. Confidence/conflicts: High for registry geography and trial design; investigational RP2 component. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • belzupacap sarotalocan (bel-sar, AU-011) with suprachoroidal microinjector and infrared laser versus sham controlClinical trial · NCT06007690Clinical trialTrial only (NCT06007690)United States · not biomarker-selected in the fetched registry summary; Primary indeterminate lesions or small choroidal melanoma. · This is investigational trial evidence and should not be treated as regulatory approval or routine access in any listed country. Some listed sites have withdrawn status, so referral requires current site confirmation. Confidence/conflicts: High for registry geography and study scope; investigational and site-status caveats apply. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • belzupacap sarotalocan (bel-sar, AU-011) with suprachoroidal microinjector and infrared laser versus sham controlClinical trial · NCT06007690Clinical trialTrial only (NCT06007690)United States · not biomarker-selected in the fetched registry summary; Primary indeterminate lesions or small choroidal melanoma. · This is investigational trial evidence and should not be treated as regulatory approval or routine access in any listed country. Some listed sites have withdrawn status, so referral requires current site confirmation. Confidence/conflicts: High for registry geography and study scope; investigational and site-status caveats apply. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • tebentafusp (Kimmtrak) plus Yttrium-90 radioembolization (TheraSphere)Clinical trial · NCT06627244Clinical trialTrial only (NCT06627244)United States · Metastatic uveal melanoma, liver-metastasis/radioembolization combination context. · Trial participation does not establish routine use of the combination. The source does not prove FDA approval for this combination or reimbursement for Y-90 plus tebentafusp in uveal melanoma. Confidence/conflicts: High for registry status and U.S. site; investigational combination. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • tebentafusp (Kimmtrak) plus Yttrium-90 radioembolization (TheraSphere)Clinical trial · NCT06627244Clinical trialTrial only (NCT06627244)United States · Metastatic uveal melanoma, liver-metastasis/radioembolization combination context. · Trial participation does not establish routine use of the combination. The source does not prove FDA approval for this combination or reimbursement for Y-90 plus tebentafusp in uveal melanoma. Confidence/conflicts: High for registry status and U.S. site; investigational combination. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • tebentafusp-tebn (Kimmtrak)Clinical trial · NCT06414590Clinical trialTrial only (NCT06414590)United States · HLA-A*02:01-positive; Neoadjuvant treatment before primary eye treatment for locally advanced primary uveal melanoma that is surgically unresectable other than complete enucleation; metastatic disease is excluded in the registry eligibility summary. · Registry status does not establish routine access, regulatory expansion beyond the approved metastatic/unresectable label, or individual eligibility. Site status differs by location. Confidence/conflicts: High for registry geography and setting; not evidence of approval or routine availability. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • tebentafusp-tebn (Kimmtrak) plus liver-directed therapies; GM-CSF (sargramostim) and BCNU components in registry intervention listClinical trial · NCT06626516Clinical trialTrial only (NCT06626516)United States · HLA-A*02:01-positive / HLA-A*0201-positive as stated in registry summary; Metastatic uveal melanoma; liver-directed therapy combination study. · This is an investigational protocol and does not establish routine use or payer coverage. The trial's exact liver-directed modality and arm details require protocol review by the treating team. Confidence/conflicts: High for registry status and U.S. site; investigational combination. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • tebentafusp-tebn (Kimmtrak) plus liver-directed therapies; GM-CSF (sargramostim) and BCNU components in registry intervention listClinical trial · NCT06626516Clinical trialTrial only (NCT06626516)United States · HLA-A*02:01-positive / HLA-A*0201-positive as stated in registry summary; Metastatic uveal melanoma; liver-directed therapy combination study. · This is an investigational protocol and does not establish routine use or payer coverage. The trial's exact liver-directed modality and arm details require protocol review by the treating team. Confidence/conflicts: High for registry status and U.S. site; investigational combination. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • tebentafusp-tebn (Kimmtrak) plus liver-directed therapies; GM-CSF (sargramostim) and BCNU components in registry intervention listClinical trial · NCT06626516Clinical trialTrial only (NCT06626516)United States · HLA-A*02:01-positive / HLA-A*0201-positive as stated in registry summary; Metastatic uveal melanoma; liver-directed therapy combination study. · This is an investigational protocol and does not establish routine use or payer coverage. The trial's exact liver-directed modality and arm details require protocol review by the treating team. Confidence/conflicts: High for registry status and U.S. site; investigational combination. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • tebentafusp (Kimmtrak) plus roginolisibClinical trial · NCT07203391Clinical trialTrial only (NCT07203391)Australia · Metastatic uveal melanoma combination study intended to prolong T-cell homeostasis. · Registry status does not establish TGA approval or PBS subsidy for roginolisib or this combination. Site status differs between Sydney and Melbourne in the fetched registry data. Confidence/conflicts: Medium-high for registry geography and intervention; HLA requirement not confirmed in fetched summary. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • tebentafusp (Kimmtrak) plus roginolisibClinical trial · NCT07203391Clinical trialTrial only (NCT07203391)Australia · Metastatic uveal melanoma combination study intended to prolong T-cell homeostasis. · Registry status does not establish TGA approval or PBS subsidy for roginolisib or this combination. Site status differs between Sydney and Melbourne in the fetched registry data. Confidence/conflicts: Medium-high for registry geography and intervention; HLA requirement not confirmed in fetched summary. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • tebentafusp (Kimmtrak) plus roginolisibClinical trial · NCT07203391Clinical trialTrial only (NCT07203391)Australia · Metastatic uveal melanoma combination study intended to prolong T-cell homeostasis. · Registry status does not establish TGA approval or PBS subsidy for roginolisib or this combination. Site status differs between Sydney and Melbourne in the fetched registry data. Confidence/conflicts: Medium-high for registry geography and intervention; HLA requirement not confirmed in fetched summary. No conflict identified. ClinicalTrials.gov — clinical-trial registry
  • EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells with fludarabine and cyclophosphamide in the study regimenClinical trial · NCT07627698Clinical trialTrial only (registry)China · CSPG4/GD2 target context in intervention name; registry record includes metastatic uveal melanoma among conditions; advanced melanoma including metastatic uveal melanoma. · Overall status is RECRUITING; this is not an NMPA approval record and should not be presented as routine availability. Confidence/conflicts: high for trial record and China site; no source conflict identified. NMPA approval not established. ClinicalTrials.gov — clinical-trial registry
  • IMCgp100 / tebentafusp compared with investigator choice of dacarbazine, ipilimumab, or pembrolizumabClinical trial · NCT03070392Clinical trialTrial only (NCT03070392)Russia · HLA-A*0201-positive; Previously untreated advanced/metastatic uveal melanoma with no prior systemic therapy in the metastatic or advanced setting and HLA-A*0201 positive by central assay, as described by the registry. · Completed trial geography does not establish current Russian regulatory approval, reimbursement, or access to tebentafusp. Investigator-choice comparators are trial arms, not country-specific recommendations. Confidence/conflicts: High for completed trial geography and setting; no conflict found. Russian routine access remains source-pending. ClinicalTrials.gov — clinical-trial registry
  • IMCgp100 / tebentafusp compared with investigator choice of dacarbazine, ipilimumab, or pembrolizumabClinical trial · NCT03070392Clinical trialTrial only (NCT03070392)Russia · HLA-A*0201-positive; Previously untreated advanced/metastatic uveal melanoma with no prior systemic therapy in the metastatic or advanced setting and HLA-A*0201 positive by central assay, as described by the registry. · Completed trial geography does not establish current Russian regulatory approval, reimbursement, or access to tebentafusp. Investigator-choice comparators are trial arms, not country-specific recommendations. Confidence/conflicts: High for completed trial geography and setting; no conflict found. Russian routine access remains source-pending. ClinicalTrials.gov — clinical-trial registry
  • IMCgp100 / tebentafusp compared with investigator choice of dacarbazine, ipilimumab, or pembrolizumabClinical trial · NCT03070392Clinical trialTrial only (NCT03070392)Russia · HLA-A*0201-positive; Previously untreated advanced/metastatic uveal melanoma with no prior systemic therapy in the metastatic or advanced setting and HLA-A*0201 positive by central assay, as described by the registry. · Completed trial geography does not establish current Russian regulatory approval, reimbursement, or access to tebentafusp. Investigator-choice comparators are trial arms, not country-specific recommendations. Confidence/conflicts: High for completed trial geography and setting; no conflict found. Russian routine access remains source-pending. ClinicalTrials.gov — clinical-trial registry
  • IMCgp100 / tebentafusp; investigator choice options in trial included dacarbazine, ipilimumab, or pembrolizumabClinical trialClinical trialReported in a clinical trialRussia · HLA-A*02:01 genotype positive was required in the pivotal study described by FDA; ClinicalTrials.gov record names advanced uveal melanoma; advanced uveal melanoma; FDA approval notice describes the pivotal trial in metastatic uveal melanoma. · The registry record overall status is COMPLETED and last updated 2026-03-17. Russian trial participation does not equal current local availability. Confidence/conflicts: high for Russian trial-site participation and study intervention; no source conflict identified. Routine Russia availability unverified. U.S. Food and Drug Administration — regulator approval notice

A clinical-trial listing or early report shows an option is being studied — not that it works, that it is safe for any one person, or that a site is enrolling today. Whether any of these fits is a conversation for your oncology team and the trial team. Last checked 2026-06-12.